Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome

REFERENCES

• Bowen DT, Hellström-Lindberg E. Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy? Leuk Res. 2001;25(1):19–21.
   PubMed Web of Science ®Google Scholar
• Cermak J, Kacirkova P, Mikulenkova D, Michalova K. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res. 2009;33(11):1469–1474.
   PubMed Web of Science ®Google Scholar
• Marx JJM, van Asbeck BS. Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta Haematol. 1996;95(1):49–62.
   PubMed Web of Science ®Google Scholar
• Gattermann N, Rachmilewitz E. Iron overload in MDS – pathophysiology, diagnosis and complications. Ann Hematol. 2011;90(1):1–10.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Aldouri MA, Sheppard L, . 1-2-dimethyl-3-hydroxypyrid-4-one an orally active chelator for treatment of iron overload. Lancet. 1987;1(8545):1294–1295.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM, Matsui D, . Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332(14):918–922.
   PubMed Web of Science ®Google Scholar
• Al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol. 1994;53(5):298–301.
   PubMed Web of Science ®Google Scholar
• Pontikoglou C, Papadaki HA. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. Hemoglobin. 2010;34(3):291–304.
   PubMed Web of Science ®Google Scholar
• Jaeger M, Aul C, Söhngen D, . Iron overload in polytransfused patients with MDS: use of L1 for oral iron chelation. Drugs of Today. 1992;28(Suppl. A):143–147.
   Google Scholar
• Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol. 2008;15(3):169–175.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O,Brien S, Ravandi F, . Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer. 2008;113(6):1351–1361.
   PubMed Web of Science ®Google Scholar
• Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res. 2007;31(Suppl. 3):S7–S9.
   PubMed Web of Science ®Google Scholar
• Rose C, Brechignac S, Vassilief D, . Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood. 2007;110(11):80–81a (abstract 249).
   Google Scholar
• Agarwal MB, Gupta SS, Visvanathan C, . Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 1992;82(2):460–466.
   PubMed Web of Science ®Google Scholar
• Maggio A, D’Amico G, Morabito A, . Deferiprone versus deferoxamine in patients with thalassemia major. A randomized clinical trial. Blood Cells Mol Dis. 2002;28(2):196–208.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, . Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassemia. Lancet. 2002;360(9332):516–520.
   PubMed Web of Science ®Google Scholar
• Piga A, Gaglioti C, Fogliacco E, . Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major. A retrospective analysis. Haematologica. 2003;88(5):489–496.
   PubMed Web of Science ®Google Scholar
• Fischer R, Largo F, Nielson P, . Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003;121(6):938–948.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kontoghiorghes GJ. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy. Hemoglobin. 2010;34(3):204–209.
   PubMed Web of Science ®Google Scholar
• Vreugdenhil G, Kontoghiorghes GJ, Van Eijk HG, Swaak AJG. Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Exp Rheumatol. 1991;9(1):35–40.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, . Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol. 2000;108(2):305–312.
   PubMed Web of Science ®Google Scholar
• Ceci A, Baiardi P, Felisi M, . The safety and effectiveness of deferiprone in a large-scale, 3 year study in Italian patients. Br J Haematol. 2002;118(1):330–336.
   PubMed Web of Science ®Google Scholar
• Hoffbrand VA. Deferiprone therapy for transfusional iron overload. Best Practice Res Clin Haematol. 2005;18(2):299–317.
   PubMed Web of Science ®Google Scholar
• Jones-Lecointe A, Green PJ, Lee HA. Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin. Clin Lab Haematol. 1991;13(3):251–253.
   PubMedGoogle Scholar
• Vreugdenhil G, Swaak AJG. Interactions between erythropoietin and iron metabolism in anaemia of chronic disorders. Eur J Haematol. 1992;48(1):56–57.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risk of serious roxicities. Expert Opin Drug Saf. 2010;9(4):633–641.
   PubMed Web of Science ®Google Scholar